As reported in Healio, Geoffrey Shapiro, MD, PhD, will receive the TAT 2019 Honorary Award for cancer drug development.
The award will be presented at TAT International Congress 2019, a European Society for Medical Oncology-sponsored conference that will be held Feb. 25-27 in Paris.
Shapiro is professor of medicine at Harvard Medical School and institute physician at Dana-Farber Cancer Institute.
“[He] has dedicated his career to developing better anticancer medicines,” Giuseppe Curigliano, MD, PhD, chair of the ESMO nomination committee, said in a press release. “His work has been a key factor in the successful advancement of a number of drugs, including CDK 4/6 inhibitors, now approved in breast cancer and under active investigation in other cancers. It is, therefore, a great pleasure for ESMO to present him the TAT 2019 Honorary Award for cancer drug development.”
Shapiro’s laboratory has made contributions toward the development of several combinations of targeted agents. He also established translational assays that can identify target engagement of these patients, according to ESMO’s press release.
In addition, Shapiro has worked to understand the effects PARP inhibitors, CDK inhibitors and other classes of agents have on the immune microenvironment.
“For many years, the TAT International Congress has been a critical venue for the presentation of translational research and discussion of all facets of early drug development, from biology of novel drug classes to clinical trial design, to monitoring of toxicities and responses, to reporting of early clinical results,” Shapiro said in the release. “There is no other place where those involved in early drug development can find such a strong and supportive community of premier investigators with international representation. It is, therefore, a great honor to be selected by my peers for the TAT Honorary Award this year, one of my proudest accolades for which I am tremendously grateful.”